NCT01363271

Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 7,260 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This is a retrospective, observational, non-interventional drug study using de-identified data from two administrative claims datasets. The study design and analysis will reflect the perspective of the commercially insured. The objectives of this study are twofold: 1. To compare the rates of re-hospitalization among patients treated with either linezolid orally or IV, or vancomycin IV for complicated skin and skin structure infections (cSSSI) or pneumonia hospitalization. 2. To compare the total direct medical costs of patients treated with linezolid orally or IV, or vancomycin IV for cSSSI or pneumonia hospitalization.

Detailed description

A sampling method is not used in this study since it is a retrospective, non-interventional claims database analysis. Pre-specified inclusion/exclusion criteria and ICD-9, NDC, HCPC codes are applied to identify the study cohorts.

Conditions

• Complicated Skin and Structure Infection
• Nosocomial Pneumonia

Interventions

Type	Name	Description
DRUG	Linezolid	IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
DRUG	Vancomycin	IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
DRUG	Linezolid	IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
DRUG	Vancomycin	IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2011-06-01
• Last updated: 2012-05-22